奥泰生物(688606) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 199,920,896.28, representing a decrease of 15.34% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 44,788,913.62, an increase of 10.50% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 37,777,315.36, reflecting a growth of 30.83% compared to the previous year[5]. - Total operating revenue for Q1 2024 was CNY 199.92 million, a decrease of 15.3% compared to CNY 236.14 million in Q1 2023[20]. - Net profit for Q1 2024 increased to CNY 44.64 million, up 10.4% from CNY 40.34 million in Q1 2023[20]. - The net profit for Q1 2024 was CNY 51,953,066.44, representing an increase of 23.4% from CNY 42,088,665.76 in Q1 2023[29]. Cash Flow - Cash flow from operating activities showed a significant decline of 122.00%, amounting to CNY 39,081,462.52, primarily due to large payments made for supplier invoices from Q4 2022[6][9]. - Cash flow from operating activities for Q1 2024 was CNY 39.08 million, a significant improvement from a negative CNY 177.68 million in Q1 2023[23]. - The company reported a tax expense of CNY 2.51 million for Q1 2024, significantly lower than CNY 5.72 million in Q1 2023[20]. - The company received CNY 192.46 million in cash from sales and services in Q1 2024, an increase from CNY 158.89 million in Q1 2023[22]. - The ending balance of cash and cash equivalents was ¥927,567,931.18, down from ¥1,457,097,364.19 in Q1 2023[33]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,140,840,306.93, a slight increase of 0.60% from the end of the previous year[6]. - The company's total liabilities increased to RMB 298,053,605.46 from RMB 284,499,705.67, indicating a rise of approximately 4.5%[17]. - The total equity attributable to shareholders reached RMB 3,838,615,607.63, up from RMB 3,827,249,132.73, reflecting a growth of about 0.3%[17]. - The company's inventory decreased to RMB 161,875,508.42 from RMB 188,594,762.48, a reduction of about 14.2%[16]. - The accounts receivable decreased to RMB 87,785,816.55 from RMB 100,869,677.68, indicating a decline of approximately 13%[15]. - The company's total current assets of RMB 3,065,860,380.34, down from RMB 3,161,447,852.41, a decrease of about 3%[15]. Shareholder Information - The company had a total of 5,035 common shareholders at the end of the reporting period[12]. - The top shareholder, Hangzhou Jingguan Investment Management Co., Ltd., held 23.33% of the shares, totaling 18,492,600 shares[12]. Research and Development - R&D investment totaled CNY 23,156,697.04, down 35.89% year-over-year, with R&D expenses accounting for 11.58% of operating revenue, a decrease of 3.72 percentage points[6]. - R&D expenses decreased to CNY 20,881,044.76, a reduction of 37.8% from CNY 33,550,901.15 in Q1 2023[28]. Earnings Per Share - Basic and diluted earnings per share were both CNY 0.56, reflecting a year-over-year increase of 9.80%[6]. - Basic and diluted earnings per share for Q1 2024 were CNY 0.56, compared to CNY 0.51 in Q1 2023[21]. Financial Ratios - The weighted average return on net assets increased by 0.20 percentage points to 1.17%[6]. - The company’s total liabilities to equity ratio is approximately 0.078, indicating a low level of financial leverage[17].